(Q42641051)

4 November 2017

Medication-related predictors of health-related quality of life in glaucoma patients enrolled in a medicare health maintenance organization (English)

1 reference

4 November 2017

1 reference

Rajesh Balkrishnan

1

1 reference

4 November 2017

J Brent Bond

2

1 reference

4 November 2017

Wesley G Byerly

3

1 reference

4 November 2017

Fabian T Camacho

4

1 reference

4 November 2017

Roger T Anderson

5

1 reference

4 November 2017

1 December 2003

1 reference

American Journal of Geriatric Pharmacotherapy

4 November 2017

1 reference

4 November 2017

1

1 reference

4 November 2017

2

1 reference

4 November 2017

75-81

1 reference

Longitudinal prevalence of major eye diseases.

4 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

Estimates of incidence rates with longitudinal claims data

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

Prostaglandin analogues in the treatment of glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

Glaucoma and quality of the life

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

Influence of glaucomatous visual field loss on health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

Glaucoma's impact on quality of life and its relation to clinical indicators. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

Functional status and well-being in patients with glaucoma as measured by the Medical Outcomes Study Short Form-36 questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

Visual function and quality of life among patients with glaucoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

Issues of aging and adherence to health interventions

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

Treatment for glaucoma: adherence by the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

Contribution of multiple glaucoma medications to visual function and quality of life in patients with glaucoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

Development of the 25-item National Eye Institute Visual Function Questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

Reliability and validity of the Ocular Surface Disease Index

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

Compliance aids--do they work?

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

Inhaled corticosteroid nonadherence and immediate avoidable medical events in older adults with chronic pulmonary ailments

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

Inhaled corticosteroid use and associated outcomes in elderly patients with moderate to severe chronic pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1543-5946%2803%2990003-1

7 January 2021

10.1016/S1543-5946(03)90003-1

Identifiers

DOI

1 reference

4 November 2017

1 reference